Mario Cozzolino, Sokratis Stoumpos, Sunil Bhandari
{"title":"更新的播客摘要欧洲肾脏最佳实践和英国肾脏协会指南治疗贫血慢性肾脏疾病。","authors":"Mario Cozzolino, Sokratis Stoumpos, Sunil Bhandari","doi":"10.1007/s12325-025-03366-6","DOIUrl":null,"url":null,"abstract":"<p><p>Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) were developed as an alternative to erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia of chronic kidney disease (CKD). In 2024, the European Renal Best Practice Board (ERBP) of the European Renal Association published a clinical practice document for the use of HIF-PHIs; in 2025, the UK Kidney Association (UKKA) updated its treatment guidelines for anaemia of CKD, including HIF-PHIs as a recommended additional therapy. This podcast provides an overview of HIF-PHIs compared to ESAs, followed by a summary of general recommendations for the treatment of anaemia of CKD, with reference to both ERBP and UKKA guidelines. Considerations for prescribing ESAs and HIF-PHIs to specific patient groups, including those with inflammation, a history of cancer or cardiovascular events, kidney transplant recipients, and hospitalised patients, are then discussed. Podcast Audio (MP4 169314 KB).</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Podcast Synopsis of Updates to the European Renal Best Practice and UK Kidney Association Guidelines for Treatment of Anaemia in Chronic Kidney Disease.\",\"authors\":\"Mario Cozzolino, Sokratis Stoumpos, Sunil Bhandari\",\"doi\":\"10.1007/s12325-025-03366-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) were developed as an alternative to erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia of chronic kidney disease (CKD). In 2024, the European Renal Best Practice Board (ERBP) of the European Renal Association published a clinical practice document for the use of HIF-PHIs; in 2025, the UK Kidney Association (UKKA) updated its treatment guidelines for anaemia of CKD, including HIF-PHIs as a recommended additional therapy. This podcast provides an overview of HIF-PHIs compared to ESAs, followed by a summary of general recommendations for the treatment of anaemia of CKD, with reference to both ERBP and UKKA guidelines. Considerations for prescribing ESAs and HIF-PHIs to specific patient groups, including those with inflammation, a history of cancer or cardiovascular events, kidney transplant recipients, and hospitalised patients, are then discussed. Podcast Audio (MP4 169314 KB).</p>\",\"PeriodicalId\":7482,\"journal\":{\"name\":\"Advances in Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12325-025-03366-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03366-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Podcast Synopsis of Updates to the European Renal Best Practice and UK Kidney Association Guidelines for Treatment of Anaemia in Chronic Kidney Disease.
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) were developed as an alternative to erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia of chronic kidney disease (CKD). In 2024, the European Renal Best Practice Board (ERBP) of the European Renal Association published a clinical practice document for the use of HIF-PHIs; in 2025, the UK Kidney Association (UKKA) updated its treatment guidelines for anaemia of CKD, including HIF-PHIs as a recommended additional therapy. This podcast provides an overview of HIF-PHIs compared to ESAs, followed by a summary of general recommendations for the treatment of anaemia of CKD, with reference to both ERBP and UKKA guidelines. Considerations for prescribing ESAs and HIF-PHIs to specific patient groups, including those with inflammation, a history of cancer or cardiovascular events, kidney transplant recipients, and hospitalised patients, are then discussed. Podcast Audio (MP4 169314 KB).
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
